Baird Financial Group
SRNE

Baird Financial Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Baird Financial Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-162,275
Closed -$1.26M – 1274
2016
Q3 		$1.26M Sell
162,275
-48,502
-23% -$327K 0.01% 693
2016
Q2 		$1.18M Sell
210,777
-50,171
-19% -$321K 0.01% 690
2016
Q1 		$1.4M Buy
260,948
+5,737
+2% +$33.3K 0.01% 624
2015
Q4 		$2.22M Sell
255,211
-15,014
-6% -$127K 0.02% 503
2015
Q3 		$2.27M Sell
270,225
-35,566
-12% -$567K 0.02% 481
2015
Q2 		$5.39M Buy
+305,791
New +$3.93M 0.05% 318

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's SRNE Position: Q4 2016 in Review

Baird Financial Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2016, closing a stake of 162,275 shares — an estimated $1.26M sold.

Baird Financial Group first reported a position in SRNE in Q2 2015 and held it in 6 quarters. The position peaked at $5.39M in Q2 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

  • Baird Financial Group reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Baird Financial Group sold 162,275 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $1.26M.
  • Baird Financial Group first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
  • Baird Financial Group's Sorrento Therapeutics, Inc. position peaked at $5.39M in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on Baird Financial Group's 13F filing for Q4 2016, filed 10 Feb 2017.